CytoSinct™ Nanobeads

Product Features

Ultra Purity

High Recovery

High Viability

Nano-sized

Bio-degradable

Bio-compatible

Cost Efficient

Product Details

• Product Comparison

  Advantages	GenScript	Vendor A	Vendor B	Vendor C
  Cell isolation performance (purity& recovery rate)	✓✓	✓✓	N/A	✓
  Cell activation (cell expansion rate/TCM+TSCM amount)	✓✓	✓	✓✓	✓
  Clinical use	✓	✓	✓	×
  No Bead-removal Step	✓	✓	×	×
  Safety	✓	✓	✓/×	×
  Cost Efficiency	✓	×	×	✓
  Customized beads service	✓	×	×	×

• Workflow

  GenScript's CytoSinct™ Nanobeads purify cells using a column-based separation method.

  *These beads are compatible with magnetic columns for cell isolation from GenScript or another vendor.

  

Product List

Application Data

• Application note- CytoSinct™ T cell isolation

  Highly Efficient CD4+CD8+T Cell Isolation from PBMCs

  Purity, recovery and viability are among the most important characters of cells post-isolation. CytoSinctTM Nanobeads are nanometer-sized and can isolate your target cells gently and efficiently, which makes your postisolation cells suitable for variety of down-stream applications.

  

  Figure 1. PBMCs were isolated using CytoSinct™ CD4 Nanobeads, human (RUO) (Cat# L00863) and CytoSinct™ CD8 Nanobeads, human (RUO) (Cat# L00864), the results shows high purity(A,B), high recovery(C) and high viability(D).

  Comparing to the similar products from the competitor, GenScript CytoSinct™ Nanobeads can provide the target cells with high purity and recovery rate.

  

  Figure 2. Subpopulation phoenotype of post-isolation cells is important for functional and phenotypic studies. Non-T subpopulations like monocyte and NK cells could impact the efficacy of T-cells or therapeutic CAR-T and TCR-T generated from the enrichment. GenScript CytoSinctTM Nanobeads for CD4 and CD8 T-cell isolation efficiently minimize non-T composition in the enrichment population.

  Highly Efficient T Cell Isolation from Apheresis

  CD4+&CD8+ or CD3+ T cell isolation are both commonly used for the relevant T cell studies. GenScript can provide high quality of both RUO and GMP grade CytoSinct™ Nanobeads, which can support your studies from bench-side to bed-side.

  

  Figure 3. Representative data comparing T cells isolation from leukopheresis samples using GenScript CytoSinctTM Nanobeads and competitor products.
  A. Shows comparison of pre and post isolation data, purity, recovery, and viability for co-isolation of CD4 and CD8 T cell from apheresis using CytoSinctTM CD4 + CytoSinctTM CD8 and competitor reagent.
  B. Shows comparison of pre and post isolation data, purity, recovery, and viability. CD3 T cell from apheresis using CytoSinctTM CD3 and competitor reagent.

  Isolated T cells using CytoSinct™ Nanobeads has a high purity and recovery rate.

• Application note- CytoSinct™ NK cell isolation

  NK Isolation using CytoSinct™ Nanobeads

  

  NK Isolation: CD3 depletion >> CD56 enrichment

  

  Efficient isolation using CytoSinct™ CD3 nanobeads & CytoSinct TM CD56 nanobeads.

  Purity of NK reaches nearly 90% after enriched by GenScript products, which is comparable with using competitor products.

• Application note- CytoSinct™ CD34+ stem cell isolation

  CytoSinctTM CD34 Nanobeads cell isolation from PBMC

  Starting Material: PBMC, ~1% CD34+. isolated by CytoSinctTM CD34 beads, comparison with Competitor CD34.

  

  Genscript CytoSinctTM CD34 nanobeads perform comparable isolation efficiency on PBMC with competitor.

• Application note- CytoSinct™ TCR αβ+ cell depletion

  Workflow of TCRαβ beads from different brands

  

  GenScript CytoSinct™ TCRαβ Nanobeads can provide a simpler One-step isolation process.
  - 2 hours less of Manufacturing.
  - One less set of tubing set.
  - 10-20% Cell Recovery.

  Things that GenScript CytoSinct™ TCRαβ Nanobeads can provide

  - Simple process: one step isolation, saving 1-2 hours of manufacturing.
  - Improved cell loss: 10-20% higher cell recovery due to one less time centrifugation.
  - Better cell status: shorter isolation process, less cell injury.
  - Less safety concern: bio-degradable, nano-sized beads, no remaining free antibody.
  - Easy in process analysis: eliminate potential background signal when performing flow cytometry test.

  

  CytoSinctTM TCR αβ Nanobeads, human

  - Starting Material: PBMCs.
  - Application: TCR αβ Depletion.
  - GS : CytoSinct TCR αβ nanobeads, human.
  - M: Competitor TCRα/β kit.

  
• Application note- CytoSinct™ universal cell isolation

  Workflow of Universal Cell Isolation

  

  Example of CytoSinct™Streptavidin Nanobeads

  

  Universal & Quick & Efficient!

Resources

CytoSinct™ Cell Isolation and Activation Solution

Free Download

Cell Isolation and Activation Flyer

Cell Isolation and Activation Flyer

Free Download

DMF Letter of Authorization (LoA)

Request

Quality Documents

Request

Strategic Cooperation

On January 11, 2025, Ucello Biotechnology Co., Ltd. announced that its independently developed umbilical cord blood derived allogeneic CD19-targeted CAR-T cell product, UC101, received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA). This is the first FDA IND approval of an umbilical cord blood derived allogeneic CAR T cell therapy program.

GenScript provided the essential raw materials, including Enceed™ T cell Activation Reagent, CytoSinct™ Cell Isolation Nanobeads (GMP) for various targets, and the CytoSinct™ 1000 instrument. The pre-conjugated, nanoparticle mediated cell isolation and activation technology, along with comprehensive global regulatory support provided by GenScript were crucial in achieving this milestone, making CAR-T cell therapy more accessible to broader range of patients.

---

Ucello Biotechnology

On November 14, 2024, Base Therapeutics Co., Ltd. announced that its independently developed, world-first base-edited universal NK cell product, NK510 Cell Injection, received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA) for the clinical treatment of advanced solid tumors. On October 22, NK510 Cell Injection received the IND approval form NMPA.

GenScript is proud to have supported the development of this groundbreaking therapy with our CytoSinct™ Cell Isolation Nanobeads (GMP) and CytoSinct™ 1000 instrument. The CytoSinct™ platform has completed FDA DMF activation, underscoring its readiness for clinical applications.

---

Base Therapeutics

Product Solutions

Cell Therapy Development Comprehensive Product Solutions

Learn more about the Cell Therapy Development Comprehensive Product Solutions.

Learn More